Our ODF Manufacturing Process: Every Step from Raw Materials to Finished Products
Author: Sihan Meng, Leyu Zhu, Pengcheng Shi
Affiliation: RSBM
Email: pengchengshi@biotechrs.com; pcspc9@gmail.com
Abstract
Oral Disintegrating Films (ODFs/OTFs) are precision-engineered polymeric dosage forms whose quality depends on tight integration of materials science, process engineering, and quality systems. This paper presents a comprehensive, step-by-step overview of our ODF manufacturing process—from raw material qualification to finished, shelf-ready products. Each stage is described with its objectives, critical process parameters (CPPs), and critical quality attributes (CQAs), highlighting how upstream decisions propagate downstream. By documenting a complete, industrially proven workflow, this paper provides a transparent reference for scalable, reproducible, and compliant ODF production across pharmaceutical, nutraceutical, and consumer health applications.
Introduction
ODFs offer rapid disintegration, accurate dosing, and water-free administration, positioning them as a compelling alternative to tablets, capsules, and liquids [1]. However, ODFs are also among the most process-sensitive oral dosage forms. Minor deviations in material properties or process conditions can result in brittleness, blocking, thickness drift, or stability failures [2].
Unlike batch-compressed solids, ODFs are produced via continuous coating and drying, requiring a systems-level approach that integrates formulation, equipment, environment, and quality control [3]. This paper details our end-to-end ODF manufacturing process to illustrate how consistency and mass-producibility are achieved in practice.
Methods
The process description is based on validated industrial operations, pharmacopeial guidance, and peer-reviewed literature. Each manufacturing step is mapped to its objectives, CPPs, and CQAs. Risk control strategies and in-process monitoring are described to demonstrate how quality is built into the process rather than inspected at the end [4].
Step 1: Raw Material Qualification
Supplier Selection and Documentation
All raw materials—including film-forming polymers, active ingredients, plasticizers, sweeteners, and stabilizers—are sourced from qualified suppliers with complete documentation (COA, specifications, traceability) [5].
Incoming Quality Control
Incoming materials are tested for identity, purity, moisture content, and key functional properties (e.g., molecular weight range for polymers). Only materials meeting predefined specifications are released for production.
CQAs: Identity, purity, moisture
CPPs: Storage temperature and humidity
Step 2: Formulation Preparation
Solution Design
Formulation design targets scalable film formation, emphasizing polymer chain entanglement, a stable viscosity window, and an effective glass transition temperature (Tg) near processing conditions [6].
Mixing and Hydration
Polymers are dispersed and hydrated under controlled shear and temperature to ensure complete dissolution and homogeneity. Active ingredients and excipients are incorporated sequentially to prevent agglomeration or phase separation.
CQAs: Viscosity, homogeneity
CPPs: Mixing speed, temperature, hydration time
Step 3: Filtration and Deaeration
Prior to coating, the solution is filtered to remove particulates and deaerated to eliminate entrapped air. This step prevents coating streaks, pinholes, and thickness variability [7].
CQAs: Absence of particulates and bubbles
CPPs: Filter pore size, deaeration time
Step 4: Precision Coating (Casting)
Coating Method
The formulation is deposited onto a moving substrate using precision coating systems (e.g., slot-die or knife-over-roll). Coating weight directly determines dry film thickness and unit dose accuracy [8].
Web Control
Tension and speed are tightly controlled to maintain uniformity across the web width and along the machine direction.
CQAs: Thickness uniformity, dose accuracy
CPPs: Coating gap, pump rate, line speed
Step 5: Controlled Drying
Multi-Zone Drying
The wet film passes through a multi-zone drying tunnel with staged temperature and airflow to remove solvent without causing surface skinning, cracking, or active migration [9].
Moisture Control
Residual moisture is adjusted to balance flexibility and stability.
CQAs: Residual moisture, film integrity
CPPs: Drying temperature profile, airflow, residence time
Step 6: Web Handling and Rewinding
The dried film is cooled, inspected, and rewound under controlled tension. Proper web handling prevents stretching, curling, or edge damage that would compromise downstream converting [10].
CQAs: Mechanical integrity
CPPs: Tension setpoints, rewind speed
Step 7: Slitting and Die-Cutting
Slitting
Master rolls are slit into narrower rolls according to unit-dose dimensions.
Die-Cutting
Films are die-cut or punched into individual doses with precise geometry. Dose accuracy is area-based; therefore, cut quality is critical [11].
CQAs: Unit dose uniformity, edge quality
CPPs: Blade condition, cutting pressure, alignment
Step 8: Primary Packaging
Packaging Selection
ODFs are packaged in high-barrier formats (sachets, stick packs, blisters) to protect against moisture, oxygen, and mechanical stress [12].
Sealing and Inspection
Sealing parameters are optimized to ensure integrity without heat damage. Inline inspection verifies seal quality and pack integrity.
CQAs: Package integrity, stability
CPPs: Seal temperature, pressure, dwell time
Step 9: Finished Product Testing and Release
Quality Control Testing
Finished products undergo release testing, including:
Content uniformity
Disintegration time
Mechanical properties
Stability (accelerated and real-time) [13,14]
Batch Release
Only batches meeting all specifications are released for distribution.
Measures
Process and product performance are monitored using [15]:
Thickness and coating weight variability
Viscosity stability over time
Yield after cutting and packaging
Defect rate per batch
Stability under defined storage conditions
These measures ensure continuous process control and improvement.
Results
Implementation of this end-to-end manufacturing process yields high batch-to-batch consistency, strong first-pass yield, and predictable scale-up from pilot to mass production. Early integration of formulation, process, and packaging decisions minimizes rework and accelerates time-to-market [16].
Discussion
The robustness of ODF manufacturing arises from treating each step as interdependent. Weaknesses introduced upstream cannot be fully corrected downstream. By embedding quality into raw material selection, formulation design, and process control, the manufacturing system remains stable under industrial conditions [17].
This holistic approach differentiates mass-producible ODFs from laboratory prototypes and supports long-term commercial sustainability.
Conclusion
Our ODF manufacturing process integrates raw material control, formulation engineering, precision coating, controlled drying, accurate converting, and protective packaging into a unified, scalable workflow. By managing CPPs and CQAs at every step, we consistently produce high-quality, shelf-ready ODF products. This end-to-end approach provides a reliable foundation for pharmaceutical and consumer health applications requiring precision, reproducibility, and regulatory readiness.
References
Fu Y et al. Expert Opin Drug Deliv. 2004;1(4):673–690.
Preis M. J Pharm Pharmacol. 2013;65(2):157–170.
Cilurzo F et al. Eur J Pharm Biopharm. 2008;70(3):895–900.
Dixit RP, Puthli SP. J Control Release. 2009;139(2):94–107.
Bala R et al. Int J Pharm Investig. 2013;3(2):67–76.
Sperling LH. Introduction to Physical Polymer Science. Wiley; 2005.
Morales JO, McConville JT. Ther Deliv. 2011;2(5):637–646.
Hoffmann EM et al. Pharm Res. 2011;28(8):1914–1922.
Borges AF et al. Int J Pharm. 2015;494(1):332–339.
Arya A et al. Int J PharmTech Res. 2010;2(1):576–583.
Shojaei AH. J Pharm Pharm Sci. 1998;1(1):15–30.
Preis M et al. Drug Dev Ind Pharm. 2014;40(2):152–160.
USP <701> Disintegration Test.
USP <905> Uniformity of Dosage Units.
Keshari R, Keshari S. J Drug Deliv Ther. 2014;4(4):1–7.
Preis M. Drug Dev Ind Pharm. 2013;39(7):1049–1057.
Cilurzo F et al. Drug Dev Ind Pharm. 2012;38(5):588–598.